Johnson & Johnson has announced data from the Phase 3 ASTRO study of TREMFYA (guselkumab) subcutaneous (SC) induction therapy in adults with moderately to severely active ulcerative colitis (UC).
C2 PHARMA has announced the approval of a Certificate of Suitability (CEP) for Oxybuprocaine Hydrochloride by the European Directorate for the Quality of Medicines and Health Care (EDQM).
Novartis UK announced MHRA approval of ribociclib for use with an AI as an adjuvant treatment for high-risk HR-positive, HER2-negative early breast cancer.
ITM has announced positive topline results from its Phase 3 COMPETE trial in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs).
Everest Medicines has announced that with the official implementation of the latest update of the National Reimbursement Drug List on 1st January 2025, NEFECON(R) will apply the NRDL pricing, which will benefit more IgA nephropathy (IgAN) patients.
SpliceBio has announced that the U.S. Food & Drug Administration (FDA) has cleared its investigational new drug (IND) application for lead program SB-007.
Gerresheimer announces that the US Food and Drug Administration (FDA) granted SQ Innovation Tentative Approval for Lasix ONYU for the home treatment of fluid overload in congestive heart failure.
iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, provides a clinical update on its lead asset, roginolisib.
As part of the UK government's efforts to create a smoke-free generation, the National Health Service (NHS) England is rolling out a new and improved pill to help people stop smoking, giving thousands of smokers a better chance to quit for good.
UK-based Concept Life Sciences (Concept) and Accelero Biostructures (Accelero) in the US have formed a partnership which will help pharma businesses worldwide speed up drug development by up to tenfold.
Everest Medicines has announced that the Department of Health of the Government of the Hong Kong Special Administrative Region, China, has accepted Everest’s New Drug Application (NDA) for VELSIPITY(R) (etrasimod).
Hua Medicine has announced that the Company has successfully completed a Phase I clinical trial on its 2nd generation GKA candidate in U.S. at the 9th China BioMed Innovation and Investment Conference (CBIIC).
